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ABSTRACT
Considerable data exist regarding the mechanisms of allostimulation and homing (the effector phases) in
graft-versus-host disease (GVHD). Current dogma suggests that target specificity involves preferential injury
to epithelial surfaces of the skin and squamous mucosae, liver, and gut. Little attention has been devoted,
however, to mechanisms of cellular targeting or to whether heterogeneity exists in target tissues with regard
to a threshold for cellular injury. A recent breakthrough in understanding the target stage of GVHD indicates
that the predominant pathway of injury to squamous epithelial cells involves apoptosis. Moreover, apoptotic
injury may be associated or unassociated with local T-cell infiltration and involves phenotypically and anti-
genically distinctive epithelial cells within the basal layer of the skin and squamous mucosa. These cells are
confined to rete ridges in the skin and retelike prominences in the dorsal tongue and are designated as
selectively targeted apoptotic rete (STAR) cells. The discovery of STAR cells in GVHD paves the way for
speculation and experimentation to determine why these subpopulations are selectively vulnerable and how
soluble and cellular effectors of apoptosis contribute to their ultimate demise. Novel approaches to GVHD
treatment derived from understanding mechanisms of selective epithelial injury are likely to use strategies to
render target cells less susceptible to the apoptosis that is ultimately responsible for organ dysfunction and
failure.
© 2004 American Society for Blood and Marrow Transplantation
KEY WORDS
Acute graft-versus-host disease ● Hematopoietic stem cell transplantation ● Target cells ●
Apoptosish
f
t
l
u
i
t
c
e
b
t
a
p
a
cACKGROUND
he Problem
Hematopoietic stem cell transplantation (HSCT)
s a highly effective therapy for numerous hematologic
alignancies [1]. In donor/recipient combinations
atched at the major histocompatibility complex
MHC), T cells may undergo allostimulation because
f minor histocompatibility antigens (miHAs) that
epresent MHC class I or II–presented peptides that
riginate from ubiquitous or tissue-associated protein
roducts [2]. Such alloreactivity may target persistent
mmunocompetent host leukocytes or residual leuke-
ic cells, thus enhancing engraftment or providing a
raft-versus-leukemia (GVL) effect, respectively [3-6].
lthough such potential beneﬁts favor the use of al-
ogeneic over autologous HSCT [7,8], graft-versus- c
B&MTost disease (GVHD) is also a consequence of the
ormer approach; it results in potentially lethal injury
o host epithelia of the skin and squamous mucosae,
iver, and gut [4,5,9,10]. Thus, a critical need exists to
nderstand the cellular and molecular basis for tissue
njury in GVHD to develop new therapeutic strategies
hat will more precisely inhibit the clinical sequelae of
ytotoxic targeting of vital organs in HSCT recipi-
nts. A major obstacle in current investigations has
een limited insight into the general mechanisms of
argeted cell death, namely, which molecular pathways
re involved and which subpopulations of cells are the
rimary targets of the disease.
In human skin, the histopathologic changes of
cute GVHD are often extraordinarily subtle. They
onsist of an often sparse superﬁcial dermal perivas-
ular lymphocytic inﬁltrate, subtle foci of lymphocyte
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3igration into the overlying epidermis, and death of
ingle cells (keratinocytes) within the lowermost layers
f the epidermis. Because skin is a readily accessible
arget organ in GVHD, it is frequently biopsied to
ssess the presence and extent of disease. However,
he histopathologic alterations that typify acute cuta-
eous GVHD are not entirely speciﬁc and fail to
lluminate the pathogenesis of this mechanistically
omplex disorder.
Conceptual Model for GVHD: Allostimulation
nd Homing Stages
We have proposed a model whereby the patho-
enesis of acute GVHD may be divided into 3 evolu-
ionary stages [11,12]. These consist of (1) allostimu-
ation, (2) tissue-directed homing, and (3) epithelial
njury within these organs. The ﬁrst 2 stages consti-
ute the extensively studied effector phase of the disease,
hereas the last represents the target phase, about
hich little is presently known. All stages are inﬂu-
nced by the production of inﬂammatory cytokines
nitiated during the pretransplantation conditioning
egimen as a consequence of iatrogenic intestinal in-
ury (eg, irradiation) related to impaired barrier func-
ion and the resultant release of endotoxin from gut
acteria [13,14].
Acute GVHD subsequent to HLA-matched
SCT is attributed to mature donor T cells reacting
gainst host miHAs. Alloreactive T cells have been
loned from patients, and their elimination from the
onor transplant inoculum will prevent disease [15].
owever, T-cell removal from the transplant is asso-
iated with an increased incidence of graft failure in
umans, as well as with an increased frequency of
eukemic relapse that is presumably due to inhibition
f the GVL reaction. Recent studies have focused on
dentifying pathogenetic differences between GVHD
nd the GVL reaction in the hope of developing
trategies for selective inhibition of the former while
reserving the latter [16-18].
During the allostimulatory stage of GVHD, the
elative contributions of CD4 and CD8 T cells in the
enesis of GVHD across miHA barriers have been a
ajor focus of experimental inquiry [19-22]. We now
now by studying relevant experimental models of
urine GVHD elicited across miHA barriers that
D8 T cells and, in certain experimental situations,
D4 T cells can mediate lethal GVHD. It is interest-
ng to note that the target cell injury in both CD8-
nd CD4-mediated forms of acute GVHD is qualita-
ively similar by conventional microscopy [21]. By
xamining the T-cell receptor (TCR) V repertoire of
ffector T cells by using CDR3-size spectratyping,
xpansion of speciﬁc V families has been identiﬁed,
orrelated with miHA differences between donor and
ost, and evaluated over the course of disease progres-
ion [23-25]. An opportunity thus emerges to poten- c
58ially modulate disease activity by targeting speciﬁc
 families that undergo clonal or oligoclonal expan-
ion during early disease. We have found, for example,
hat HSCT with appropriate positive selection for
CR V CD4 and CD8 T-cell subsets that are
xpanded during allostimulation results in fatal
VHD induction, whereas mice that undergo trans-
lantation with nonexpanded T cells survive with
inimal morbidity [25].
During allostimulation, the CD4 molecule is a
o-receptor for the interaction of the TCR/CD3 com-
lex with a speciﬁc antigen bound by MHC class II
olecules on antigen-presenting cells. CD4, a struc-
ural member of the immunoglobulin superfamily,
ontains 4 globular domain–like regions (D1-D4) and
complementary determining regions (CDR) in each
omain. These CDRs are potential sites for protein/
rotein interactions. Synthetic peptides derived from
DR sequences possess binding properties similar to
hose of the parent protein [26,27]. Thus, recent work
as also focused on selective inhibition of allostimu-
ation via discovery and application of synthetic pep-
ides that speciﬁcally mimic CDR3 region–mediated
inding [28,29].
Although allostimulation is likely to be enhanced
y increases in proinﬂammatory cytokines elicited by
ut injury during the conditioning regimen, allospe-
iﬁc T cells themselves are capable of contributing to
ncreasing cytokine levels. These cytokines, along
ith locally secreted ones in target tissues, play a key
ole in GVHD by inducing endothelial molecules that
otentially facilitate leukocyte adhesion in vivo. Hom-
ng of speciﬁc effector V T-cell families to micro-
ascular beds within target organs is mediated by ex-
ression of a coordinated array of cytokine-inducible
dhesion molecules displayed on the lumenal surfaces
f endothelial cells; this facilitates progressive binding
nd eventual diapedesis of effector leukocytes. We
ave learned that one of these, tumor necrosis factor
TNF)-, is stored in sizable quantities in mast cells
hat express immunoglobulin E/FcRI receptors and
hat surround postcapillary venules in human and mu-
ine dermis [30,31]. Degranulation of these mast cells
nd the resultant local TNF- release precedes effec-
or T-cell inﬂux in experimental GVHD [32]. More-
ver, animals treated with peptide analogs that inhibit
mmunoglobulin E/FcRI interactions, as well as
ast cell–deﬁcient murine transplant recipients, show
melioration of GVHD [32,33]. Thus, homing of ef-
ector T cells to skin and squamous mucosae is medi-
ted in part by adhesion molecules that are induced by
oth circulating and locally secreted cytokines. Mol-
cules relevant to T-cell recruitment to extracutane-
us target tissues in GVHD include lymphocyte Peyer
atch adhesion molecule, or 47 integrin, an impor-
ant homing integrin on alloreactive gut-homing T
ells. In this regard, donor T cells genetically deﬁcient
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Selectively Targeted Apoptotic Rete Cells in GVHD
Bn 47 develop less intestinal GVHD, whereas cuta-
eous GVHD and GVL responses are not diminished
34].
Organ-directed homing of effector T cells is as-
umed to relate, in part, to adhesive interactions that
avor effector cell accumulation in certain organs and
issues, such as skin/squamous mucosae, liver, and gut.
he precise mechanisms responsible for epithelial in-
ury in these tissues have remained elusive, however.
ne reason for this has been the inability to purify and
tudy those epithelial elements that are initially prone
o cytotoxic injury.
ELL SPECIFIC-TARGETING IN GVHD: THE ROLE OF
ELECTIVELY TARGETED APOPTOTIC RETE CELLS
In contrast to the effector stages of allostimulation
nd homing, considerably less is known of the target
hase in GVHD. Original descriptions in the rhesus
onkey model detailed epithelial cell death character-
zed by the perimeter apposition of aggressor lympho-
ytes to affected cellular targets [35]. This phenome-
on, termed satellitosis, implied a requirement for
irect interaction of inﬁltrating effector lymphocytes
n the genesis of tissue pathology. In mouse models,
e initially described injured cutaneous epithelial cells
s dyskeratotic because of their intensely eosinophilic
ytoplasm, which resembles aggregated keratin [36].
uantitation of dyskeratotic target cells (the dyskera-
otic index) proved to correlate with the number of T
ells in donor inocula, disease severity, and treatment
esponses [36-38]. The term dyskeratotic conveyed lit-
le, however, concerning the pathogenesis of target
ell injury.
In 1996, Gilliam et al. [39] showed that the mech-
nism of squamous epithelial target cell injury in ex-
erimental GVHD was apoptosis, a ﬁnding now val-
dated in human skin [40]. Apoptosis as a mechanism
f GVHD target cell injury suggested a fundamental
ole for expression and ligation of death receptors (eg,
as, TNF receptor [TNFR]–1, and TNF-related
poptosis-inducing ligand [TRAIL]). Although apop-
otic cells are often directly associated with emigrant
cells, in certain experimental conditions in which
ytokines (eg, TNF-) are of established importance,
hey also occur before T-cell inﬁltration [40]. Such
ndings indicate a potential role for soluble mediators
n the generation of apoptotic target cells [39]. More-
ver, apoptotic cells were not diffusely distributed in
he basal cell layer, as traditional dogma suggested.
ather, they proved to be spatially restricted to basal
ell layer domains at the tips of human epidermal rete
idges, rete ridge–like prominences (RLPs) of murine
ongue, and bulge regions of hair follicles [39,41]. In a
eminal observation almost 2 decades ago, Sale et al.
42] demonstrated human rete ridges to be putative c
B&MTites of early cytotoxic targeting in GVHD. However,
urine skin, unlike that of humans, is devoid of rete.
he RLPs of the dorsal tongue, however, represent
xperimental surrogates for human cutaneous epider-
al rete ridges, and the target cells that they and
nalogous cutaneous retia harbor are designated as
electively targeted apoptotic rete (STAR) cells.
TAR CELLS ARE PHENOTYPICALLY DISTINCTIVE
MONG BASAL CELLS
If STAR cells are authentic targets in GVHD,
hen they should be anticipated to attract emigrant
ffector T cells that have homed to skin and squamous
ucosal surfaces. However, not all inﬁltrating T cells
epresent allostimulated effectors. One method to
dentify T cells in situ that have undergone clonal or
ligoclonal expansion during allostimulation is by the
se of V spectratype analysis [23-25]. During allo-
timulation, speciﬁc T-cell families, deﬁned by their
CR V use, become clonally expanded. CDR3-size
pectratyping permits identiﬁcation of these overrep-
esented subpopulations that then may be identiﬁed in
issue by using V-speciﬁc monoclonal antibodies.
mmunohistochemistry with V-speciﬁc antibodies
ermits morphologic assessment of cell/cell interac-
ions between putative target epithelial cells and au-
hentically allostimulated T-cell subpopulations (as
pposed to nonspeciﬁc responders). Indeed, there has
roven to be a consistent physical association consist-
ng of direct apposition of speciﬁc allostimulated V
-cell families to STAR cells in experimental murine
odels of GVHD [43]. Association of effector T cells
nd STAR cells provides validation at a molecular
evel to the pivotal observation of Sale et al. [42] of
ete-associated targeting in GVHD.
One possible explanation for the in situ relation-
hip between speciﬁc V families of allostimulated T
ells and STAR cells in GVHD could relate to pref-
rential adhesive interactions between these 2 cell
ypes. In searching for relevant adhesive proteins, Kim
t al. [44] have found that STAR cells of the lingual
quamous mucosa express CD106 (vascular cell adhe-
ion molecule-1) in experimental models of GVHD.
D106 is the receptor for the leukocyte-associated
ntegrin VLA-4 [45]. It is normally expressed by mi-
rovascular endothelial cells as a component of the
ytokine-inducible adhesion cascade that orchestrates
patial localization and diapedesis of tissue-homing
eukocytes during the early stages of inﬂammation
45,46]. TNF-, a key cytokine in GVHD, has a
ajor role in determining CD106 expression [47-53].
n addition to its capacity to mediate leukocyte bind-
ng, CD106 also may function as a co-stimulatory
olecule in antigen-driven immune responses, in-
luding allogeneic co-stimulation in the setting of
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3xperimental GVHD [54,55]. Allostimulated donor T
ells capable of eliciting murine GVHD show in-
reased VLA-4 expression during the allogeneic ex-
ansion where speciﬁc V families clonally expand
56]. In murine models, antibodies to CD106 and its
eceptor have been shown to inhibit disease [55,57].
he inducible expression of CD106 by STAR cells in
VHD provides additional evidence that these cells
re distinct from other basal epithelial cells and pro-
ides potential insight into mechanisms responsible
or selective targeting of speciﬁc epithelial subpopu-
ations.
The notion of the existence of STAR cells, as
ircumstantially inferred by inﬁltration of speciﬁc V-
xpressing T cells and preferential expression of ad-
esion molecules such as CD106, has been signiﬁ-
antly fortiﬁed by the recent observation of Whitaker-
enezes et al. [43] that STAR cells abundantly
xpress a speciﬁc cytoskeletal protein termed cytoker-
tin 15 (K15). Differential cytokeratin expression pro-
ides a potentially important tool to isolate and study
TAR cells to deﬁne how they differ from other
pithelial cells in the basal cell layer with respect to
heir apparent vulnerability to selective apoptotic in-
ury. Perhaps even more importantly, the presence of
15 in STAR cells may provide fundamental insight
nto the mechanisms of targeting.
As early as 1986, Guillen et al. [58] observed that
ertain murine GVHD effector cells possessed phe-
otypic and antigenic overlap with large granular lym-
hocytes and natural killer cells that targeted rapidly
ividing target cells (eg, certain tumor cells). They
uggested that the preferential injury to epithelial cells
n GVHD may relate to the proliferative phases of the
ell cycle (eg, basal keratinocytes in skin). Bickenbach
59] subsequently demonstrated that basal cells in the
ete ridge–like domains of murine tongue (where
15 STAR cells are found) have characteristics of
pithelial stem cells. Indeed, K15 is additionally ex-
ressed at the tips of rete ridges of skin [43] and in the
ulge regions of murine hair follicles [60]—sites
here stem cells have been shown to reside [61-64].
pithelial stem cells are not normally highly prolifer-
tive; rather, by deﬁnition, they cycle very slowly and
re relatively undifferentiated. Upon proliferative
timulation, however (eg, by certain cytokines or
rowth factors), stem cells can divide to become an
mmediately suprabasal population termed transit am-
lifying cells [65]. Transit amplifying cells, unlike their
mmediate precursors, do not retain [3H]thymidine
abel over time after a single pulse, but they do express
D71 (transferrin receptor) [66]. In normal skin, the
ransition from stem cells/transit amplifying cells to
ostmitotic maturing squamous epithelial cells is ac-
ompanied by a molecular switch from an antiapop-
otic phenotype (eg, Bcl-XL expression) to a proapop-
otic one (eg, Bax expression) [67]. In GVHD, STAR s
60ells are under the inﬂuence of a variety of soluble
rowth and differentiation factors, as well as proapop-
otic stimuli; some of these originate with the condi-
ioning regimen [68]. Such observations are provoca-
ive as to how soluble factors may evolve and conspire
o facilitate or ultimately result in selective apoptotic
njury to cells spatially restricted within a microdo-
ain that overlaps signiﬁcantly with the stem cell/
ransit amplifying cell compartment of the squamous
pithelium.
OLUBLE AND CELLULAR EFFECTORS IN STAR CELL
NJURY: CLUES TO THE PATHOGENESIS OF GVHD
ISSUE DAMAGE
Target cell injury in GVHD is likely to involve
nterplay between soluble and cellular effectors of
poptosis. Gilliam et al. [39] have suggested such in-
eractions in studies in which apoptotic cells were
uantiﬁed over time in HSCT combinations in which
hole T cells, CD8 T cells, and T cell–depleted
ransplants were administered to appropriate recipi-
nts (Figure 1). It is interesting to note that animals
hat received whole T cells, but not those that re-
eived CD8 T cells or T cell–depleted transplants,
isplayed apoptosis by day 7, a time that preceded the
nﬂux of effector T cells. One explanation implicated
role for CD4 T cells in disease when co-adminis-
ered with CD8 T cells and raised the possibility that
oluble factors may contribute independently of direct
-cell inﬁltration. One candidate molecule is TNF-,
cytokine of established importance in experimental
VHD [69,70] and one that has the intriguing ability,
nder certain conditions, to induce an apoptotic mo-
ecular cascade by binding to TNFR-1 receptors and
o induce a proliferation/activation cascade by binding
o TNFR-2 receptors on target cells [71]. It is of
onsiderable interest, therefore, that some of the ear-
iest alterations seen in murine models before T-cell
nﬁltration involve epithelial proliferation coupled
ith early apoptosis (G.F.M., unpublished data). In
his regard, we have also shown that systemic priming
ith anti–TNF- antibodies inhibits early target cell
njury only in strain combinations in which CD4 T
ells, but not CD8 T cells, produce GVHD pathology
32]. Moreover, administration of recombinant
NF- in organ culture produces apoptotic injury to
15-expressing STAR cells with similarities to that
een in experimental GVHD [43]. STAR cell apopto-
is so induced is potentiated when TNF- is admin-
stered with interleukin-1, and these 2 cytokines have
ecently been emphasized to be of critical importance
n the evolution of experimental acute GVHD [72].
In aggregate, it now seems that target cell apopto-
is is selective, involving some but not all basal and
uprabasal squamous epithelial cells equally. More-
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Selectively Targeted Apoptotic Rete Cells in GVHD
Bver, it is likely that selective apoptotic injury to
VHD target cells, or STAR cells, involves both
oluble and cellular pathways, and the underlying vul-
erability of STAR cells to apoptosis may in part
elate to pathologic alterations in proliferation/differ-
ntiation inherent to the soluble phase of this disease.
t is unlikely, however, that soluble factors released
xclusively during the conditioning regimen account
or most of the apoptotic injury because signiﬁcant
-cell homing and apoptosis does not develop in ir-
adiated recipients of syngeneic transplants (G.F.M.,
npublished data). In this regard, it is important to
onsider that whereas increases in systemic cytokines
re initiated at the time of the conditioning regimen,
hey are further enhanced as a consequence of allo-
timulation, as well as at the time when additional gut
njury develops in relationship to the cellular targeting
hase of the disease (Figure 2).
RANSLATIONAL STRATEGIES TO OVERCOME TARGET
ELL APOPTOSIS: WHAT WE NOW MUST LEARN
Fundamental to the identiﬁcation of maneuvers to
nterrupt GVHD tissue injury at the targeting stage is
igure 1. STAR cells and effects of soluble and cellular effectors o
etelike prominences of the murine tongue and contain K15 (here
xposure to TNF- and interleukin-1 in vitro [43], they undergo
ediated deoxyuridine triphosphate nick-end labeling staining (low
egions by effector T cells (soluble phase, here depicted by inset sh
xperimental conditions in which cytokine effects are more pronoun
ed bars [CD8 T-cell HSCT] versus yellow bars [T cell–depleted c
ollowed by a second peak associated with a local inﬂux of effector Tfurther understanding of the molecular underpin- d
B&MTings of the apoptotic cascade. Immunologically me-
iated apoptosis involves initial ligation of death re-
eptors expressed on the target cell membrane. With
egard to GVHD, relevant receptors include TNFR-1
nd CD95 (Fas). Upon binding with an appropriate
igand (eg, soluble TNF- or membrane-associated
as ligand expressed by speciﬁcally allostimulated V
-cell subsets), receptor activation results in recruit-
ent of an adapter molecule and an initiator caspase
caspase-8), resulting in the formation of a death-
nducing signal complex [73-75]. A proapoptotic cas-
ade is thus initiated. Activation of caspase-8 results in
ctivation of various downstream caspases, including
aspase-3, caspase-6, and caspase-7. An alternative
athway has been described that requires the release
f cytochrome c from mitochondria, with subsequent
ctivation of caspase-9 [76-78]. Apoptosis induced via
itochondria differs from the ﬁrst pathway in that
aspases-8 and -3 tend to be activated downstream of
itochondria, with the formation of death-inducing
ignal complex permitting only limited caspase-8 ac-
ivation. Cells that undergo the apoptotic pathway
xtrinsic to mitochondria have been referred to as type
cells, whereas cells that involve intrinsic (mitochon-
D. STAR cells are localized to human epidermal rete ridges and
by indirect immunoﬂuorescence; upper left). In GVHD and upon
otic injury, as deﬁned by terminal deoxynucleotidyl transferase–
). During the interval that precedes local inﬁltration of STAR cell
RLP stained for CD3), signiﬁcant apoptosis may be observed for
] (graphically represented in blue bars [whole T-cell HSCT] versus
HSCT]). STAR cell apoptosis related to the soluble phase is then
llular phase; here depicted by inset showing RLP stained for CD3).f GVH
shown
apopt
er left
owing
ced [39
ontrol
cells (cerial) apoptotic machinery have been designated as
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362ype II cells. Notably, overexpression of Bcl-2 or
cl-XL prevents caspase-8 and caspase-3 activation
nd apoptosis only in type II cells [76]. However,
ecent ﬁndings indicate that in certain cells, mito-
hondrial dependence may be the rule for both the
xtrinsic and intrinsic pathways (J. Farber, Thomas
efferson University, personal communication, 2004).
umerous pharmacologic strategies exist to promote
nd interrupt various components of apoptotic cas-
ades, including those induced by TNF- and Fas, at
evels both intrinsic and extrinsic to mitochondrial
articipation [79-85]. Accordingly, it will be critical to
etermine how STAR cells may differ from suprabasal
ells and from their nontargeted neighbors within the
asal cell layer with respect to molecular triggers for
poptosis induction.
In all probability, the most successful therapeutic
trategies for abrogating tissue injury in GVHD will
nvolve blockade of more than 1 of the 3 evolutionary
tages of disease pathogenesis. Proinﬂammatory mol-
cules (eg, endotoxin/lipopolysaccharide) and cyto-
ines circulate even before allostimulation (as a con-
equence of the conditioning regimen) and have the
otential to drive and intensify allostimulation, hom-
ng, and cell-speciﬁc targeting [68]. As previously
oted, because signiﬁcant apoptosis of STAR cells
oes not occur in recipients of syngeneic HSCTs, it is
nlikely that the conditioning regimen alone is sufﬁ-
ient to produce signiﬁcant target cell apoptosis.
onetheless, in settings in which conditioning regi-
en and allostimulation together fuel systemic cyto-
ine levels, we have learned that apoptotic injury to
TAR cells may actually precede local homing of
ffector T cells [39]. Accordingly, systemic, as well as
ocally secreted, cytokines (eg, TNF- and interleu-
in-1) may actually prime STAR cells for their even-
ual demise by decreasing their innate threshold for
poptosis. Indeed, preliminary data in our laboratory
ndicate upregulation of proapoptotic proteins in
TAR cells in vivo before effector T-cell inﬁltration
nd in vitro after exposure to relevant cytokines
G.F.M., unpublished data).
Recognition of STAR cells in GVHD has a num-
er of important implications for translationally rele-
ant future research. If STAR cells are preferentially
ulnerable to apoptosis as a result of constitutive or
nductive features (eg, differential display of miHAs or
eath receptors), then it may be possible to modulate
VHD by blockade at this level. A more intriguing
ossibility, however, is that manipulation of cell-cy-
ling, proliferation, activation, or differentiation pro-
rams, which may be inﬂuenced by the soluble phase
f GVHD, may also alter the threshold for apoptosis
n a manner that would protect against cell injury.
quamous epithelial homeostasis is maintained nor-
ally by a delicate balance between cells protectedigure 2. Overview of effector pathways potentially mediating
TAR cell apoptosis. The conditioning regimen (eg, ionizing irra-
iation) produces injury to gut mucosal epithelium, which consists
f mucin-producing goblet cells (cell to left in central diagram), M
ells that normally communicate antigenic signals to intimately
ssociated gut immunocytes (cell to right), and ciliated cuboidal
pithelial cells (2 middle cells). This injury permits the inﬂux of
ndotoxin/lipopolysaccharide and directly stimulates cytokine se-
retion. This initial wave of cytokines (lighter gray arrows) assists in
romoting immune interactions inherent to allostimulation, in
hich speciﬁc V donor T cells become clonally expanded. Cyto-
ines produced during allostimulation (darker gray arrow), along
ith those already circulating from the conditioning regimen, to-
ether have the potential to mediate the induction of adhesion
olecules in speciﬁc microvascular beds, resulting in tissue-speciﬁc
oming of effector cells. Squamous epithelial targets (here diagram-
atically depicted as a retelike prominence of the dorsal tongue),
owever, have been already altered via exposure to cytokines elic-
ted during the conditioning regimen and allostimulation (soluble
hase). This priming may result in (1) adhesion molecule induction
hat promotes leukocyte binding, allostimulation, or both and (2)
nduction of proapoptotic proteins through ligation of cytokine
eceptors (eg, TNFR-1) or alterations in proliferation/activation
athways. Once localized to target tissues, effector T cells (black
rrows; cells with black nuclei) may mediate epithelial apoptosis and
referentially affect STAR cells (deﬁned by cells with stippled
uclei) via cell/cell interaction through ligation of death receptors
eg, Fas/Fas ligand). Similar allospeciﬁc targeting in the gut further
rives the process by enhancing liberation/secretion of proinﬂam-
atory mediators. Thus, STAR cell apoptosis is likely to involve therom apoptosis (eg, stem cells within the basal cell
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Bayer) and those that progressively express proapop-
otic molecules (eg, maturing postmitotic cells within
uprabasal layers). Such a balance in part relates to
although it is not directly caused by) the prolifera-
ion/differentiation program of the cell. Thus, a fun-
amental issue is whether factors implicit to the sol-
ble phase of GVHD alter epidermal kinetics and
ctivation in a manner that promotes the induction of
poptosis. Accordingly, one might anticipate that sub-
opulations of cells with intrinsic differences in pro-
iferation/differentiation programs (eg, STAR cells
nd their immediate progeny) might be selectively
ffected by growth and proapoptotic factors in
VHD. Indeed, it has recently shown that repifermin
keratinocyte growth factor-2) reduced the severity of
VHD without inhibiting donor T-cell responses to
ost antigens and preserved the GVL effect [86].
hese data supplement a growing database indicating
he therapeutic potential of epithelial growth factors
n the prevention of GVHD in target organs [87-90].
It is likely that the most effective attempts to
brogate GVHD at the level of inhibiting selective
pithelial apoptosis will involve blockade of proapop-
otic molecular pathways triggered by both the soluble
nd cellular phases of tissue injury. Strategies designed
o selectively tip the cell death scale toward antiapop-
otic pathways may provide novel means for protect-
ng epithelial targets while not affecting the therapeu-
ically desirable elimination of residual leukemic
lements.
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